It looks like his best bet would be a clinical trial Have you looked into Daclatasvir?
I found this study in San Antonio
An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease
https://clinicaltrials.gov/ct2/show/study/NCT02262728?term=Daclatasvir+genotype+2&recr=Open&state1=NA%3AUS%3ATX&rank=2#contacts
It looks like he needs to be treatment naive but maybe they are looking at other groups so still best to get on their radar his liver doctor should be able to help him get in contact with a clinical trial.
Also found this
http://www.hepatitisc.uw.edu/pdf/treatment-infection/treatment-genotype-2/core-concept/all
Daclatasvir plus Sofosbuvir: This investigational pangenotypic NS5A replication complex inhibitor is currently in phase 3 trials. In study AI444-040, a phase 2 trial involving patients with genotypes 1, 2, and 3, a 24-week course of daclatasvir 60 mg once daily plus sofosbuvir 400 mg once-daily, with or without ribavirin, produced SVR rates of 86% to 93% in patients with genotype 2 or 3, and was well-tolerated and safe. Additional phase 2 trials with daclatasvir in combination with sofosbuvir are ongoing. Daclatasvir for 12 weeks combined with peginterferon lambda and ribavirin for 12 or 24 weeks is under study in a phase 3 trial for patients with genotype 2 or 3 infection.
Just wanted to add I was diagnosed with cirrhosis in Jan 2008 and developed varicies that needed banding back in 2012 had to have 4 sessions to eridicate them. Anyway I am still here and get checked every year for reoccurance and so far so good.
I was in the same boat since 01/2008 cirrhosis with no medicine to take just waiting for bad things to happen. Cirrhosis and hep c are both usually slow acting a person can continue for many years where he and I are now.
So hang in there other drugs are coming hopefully soon
Lynn
Lynn thank you so much for your information and encouraging words. I will for sure ask our doctor about getting into some of these trials.
I'm praying for all hep c genotypes to be 100% curable. I can't believe how far science and research has come in just the past few years. I believe that someday hep c will be "simple" to cure.
I am just so scared that he will become more and more ill before they find the answer for him but it's out of my hands, only the doctors can fix him so in the meantime I try to be positive and encouraging. He has always been the stronger of us two, my rock so it's my turn to step up to the plate and be strong. Sometimes it just helps to talk to people who understand exactly what we are going through.
Thank you so much again
Hopefully this new hcvguidlines update including daclatasvir for GT2 will help you finally achieve SVR
see my post
http://www.medhelp.org/posts/Hepatitis-C/HCV-Guidelines-UPDATED-8-7-2015--incl-daclatasvirand-more/show/2705338
Sorry I meant to say best wishes for your husband to achieve SVR
http://www.hcvguidelines.org/full-report/unique-patient-populations-patients-decompensated-cirrhosis
Accessed August 8, 21015
Patients with HCV genotype 2 or 3 infection with decompensated cirrhosis (moderate or severe hepatic impairment; Child Turcotte Pugh [CTP] class B or C) should be referred to a medical practitioner with expertise in that condition (ideally in a liver transplant center).
Rating: Class I, Level C
Recommended regimens for patients with HCV genotype 2 or 3 infection who have decompensated cirrhosis (moderate or severe hepatic impairment; CTP class B or C) and who may or may not be candidates for liver transplantation, including those with hepatocellular carcinoma.
Daily daclatasvir (60 mg), sofosbuvir (400 mg), and low initial dose of RBV (600 mg, increased as tolerated) for 12 weeks is recommended for patients with HCV genotype 2 or 3 infection who have decompensated cirrhosis and who may or may not be candidates for liver transplantation, including those with hepatocellular carcinoma.
Rating: Class II, Level A
Daily sofosbuvir (400 mg) and weight-based RBV (1000 mg [75 kg]) (with consideration of the patient’s creatinine clearance rate and hemoglobin level) for up to 48 weeks is recommended for patients with HCV genotype 2 or 3 infection who have decompensated cirrhosis and who may or may not be candidates for liver transplantation, including those with hepatocellular carcinoma.
Rating: Class IIb, Level B